The Endometriosis Treatment Market Has Witnessed Robust Growth in North America and Asia Pacific

 


Endometriosis is a chronic disease in which tissue that normally lines the uterus grows outside the uterus. It affects around five to ten per cent women of childbearing age. Endometriosis most commonly involves ovaries, fallopian tubes, and the tissue lining the pelvis. The most common symptoms include pain during urination, pain after intercourse in pelvic area, pain in lower back during menstrual period, pain in pelvic area before menstrual cycle, excessive bleeding between periods, nausea during menstrual cycle, diarrhea, fatigue, and constipation. Effective treatments, such as hormones and excision surgery, are available. The endometriosis treatment market growth is mainly driven by the increasing prevalence of endometriosis.

According to the Endometriosis Foundation of America, endometriosis affects around 200 million women worldwide and about 1 out of every 10 women in the United States. It affects women mostly in their reproductive years and can even affect adolescents who have just started to have their periods. Endometriosis is classified into four stages, such as severe, moderate, mild, and minimal, based upon the depth, extent, and exact location of the endometriosis implants, the presence and size of endometrial implants in the ovaries, and the presence and severity of scar tissue. Therefore, with increasing incidence of endometriosis, the demand for endometriosis treatment is also increasing.

For instance, in May 2019, AbbVie, in cooperation with Neurocrine Biosciences, launched ORILISSA (elagolix) 200 mg BID dose for the treatment of moderate to severe pain associated with endometriosis. Moreover, in July 2018, the U.S. Food and Drug Administration (FDA) approved elagolix (Orilissa), the first drug developed for the treatment of moderate to severe pain from endometriosis. Thus, frequent research and development activities to accelerate the development of endometriosis treatment is a major factor driving the endometriosis treatment market growth. However, lack of education and lack of awareness is a big reason endometriosis goes undetected.

The endometriosis treatment market has witnessed substantial growth in the Asia Pacific due to increasing prevalence of endometriosis in this region. According to the Endometriosis Society of India, around 25 million women in India suffer from this condition. Thus, in June 2019, Federation of Obstetrics and Gynaecological Societies of India (FOGSI) in collaboration with Bayer Zydus Pharma launched VISION to understand the current usage pattern of various therapeutic options in Endometriosis and develop an algorithm to guide doctors on care management of endometriosis, based on different patient profiles.

Significant efforts are being made to improve the methods of diagnosis, as there is a high demand for endometriosis treatment.

Comments

Popular posts from this blog

The Emergence of COVID-19 to Augment Growth of the Outsourced Drug Discovery Market

Otoscope Market Is Gaining Major Traction with Industry Leader Otonexus Medical Technologies Introducing Ultrasound Sensor, Which Aids Middle-Ear Infection Diagnosis

Increasing Demand for Healthcare Education to Augment the Healthcare Education Solution Market Growth